Current projects

Below are examples of current work from the AI Imaging Hub.

Christina Messiou discusses a scan with another member of staff at The Royal Marsden

AI quantification of bone disease on whole body MRI

Funded by a National Institute for Health Research (NIHR) ‘Invention for Innovation’ (i4i) award, the aim of this project was to develop, test and evaluate a novel computer software toolkit to automatically process images from whole-body MRI in patients with metastatic bone disease. The software was shown to reliably and accurately assess the extent of bone disease in prostate cancer patients as part of an imaging clinical trial.

Find out more about the i4i award on the NIHR website.

Real-world multicentre testing of in-house developed software

Taking forward the work of the original i4i award, the aim is to real-world test the performance of our software in patients with bone disease from prostate cancer and myeloma in two large multi-centre clinical trials. We will also evaluate the end user interface for the software and develop appropriate training modules, determine the cost effectiveness of using whole body MRI with our software over conventional imaging assessment methods and investigate possible commercial models for wider NHS adoption in the future.

Find out more about the i4i award on the NIHR website.

Big-Data solutions towards better understanding of prostate cancer

Funded by a European Horizon 2020 grant, the aim is to build an EU-wide repository of multi-parametric MRI examinations and related clinical and pathological data dedicated to prostate cancer. This will enable experimentation of AI-based solutions to improve diagnosis, characterisation, treatment and follow-up, contributing to a more precise and personalised management of prostate cancer patients.

Find out more about the study

State-of-the-art imaging to assess effectiveness of cancer therapies

Funded by Prostate Cancer UK, the aim is to determine if whole-body MRI measurements can provide timely information about the treatment response, disease progression and cancer tissue changes in patients with metastatic advanced prostate cancer, when compared with current standard clinical, imaging and biochemical assessments.

Find more about the study

Radiomics portfolio

The AI Imaging Hub has a mature radiomics pipeline which is supporting a number of projects to explore how features in imaging data can be used for better diagnosis, stratifying risk and personalised treatment selection.


CeleScan provides an AI-powered, deep learning solution for speeding up MRI scan times used in the diagnosis of cancer.  The company was born from a collaboration between the Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and purpose-led digital transformation provider, Sopra Steria. The formation of this joint venture company, comprised of medical teams, research teams and  digital transformation expertise, is an example of unrivalled medtech collaboration, leading to the best possible solution for clinicians and patients alike.

Find out more about CeleScan